Sacituzumab govitecan in breast cancer

Xiaojun Wang, Jiongjie Chen, Hua Xiao, Yang Shi
2021 Translational Breast Cancer Research  
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 receptor (HER2) on cancer cell surface. Approximately 15% of breast cancer (BC) patients were diagnosed with TNBC and had the worst prognosis among all subtypes of BC (1). Currently, chemotherapy remains to be the backbone for treatment of metastatic TNBC (mTNBC). However, standard chemotherapy is associated with low
more » ... sponse rates (10% to 15%) and short progression-free survival (PFS) (2 to 3 months) among patients with pretreated mTNBC. In recent studies, several novel drugs including PD-1/PD-L1 inhibitors and PARP inhibitors showed promising results for the treatment of TNBC in front lines (1,2). Based on IMpassion 130, FDA approved the combinational treatment of Atezolizumab and nab-paclitaxel in patients with advanced PD-L1-positive (defined as PD-L1 stained tumor-infiltrating immune cells (IC) of any intensity covering ≥1% of the tumor area) TNBC as first-line treatment. The median PFS of Atezolizumab/nab-paclitaxel combinational treatment group was 7.5 months, while it was 5 months with nab-paclitaxel single treatment in PD-L1-positive subset (hazard ratio, 0.62; 95% CI, 0.49-0.78; P<0.001). Overall survival (OS) in the combinational treatment group was 25.0 months, while it was 15.5 months with nab-paclitaxel
doi:10.21037/tbcr-21-28 fatcat:acsvmhtcije7vftegtcrp5uw2q